Pfizer’s Successful Covid-19 Vaccine Trial in Adolescents Brings New Hope For Population Immunity And Safe School Re-Openings

Positive news comes from Pfizer this week as they announced the Phase 3 study of their Covid-19 vaccine prevented symptomatic disease and was well-tolerated by adolescents ages 12 to 15.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive